GO-Dx Corporation Ltd

GO-Dx Corporation Ltd

Biotechnology Research

Revolutionizing Health, Empowering Humanity - Innovative Technology for Next-Level Diagnostics and Wellness

About us

GO-Dx is a pioneering biotech developer realizing innovative-revolutionary technologies to facilitate personalized medical profiles at a molecular level, and enable patients and their families can live their best lives. We envision a future where every individual has access to personalized and accurate health information at the molecular level, to facilitate decisions about their health and wellness. As such, we are dedicated to advancing medical technology and improving patient outcomes through our bio-ceuticals, mRNA mapping-analytics, and miRNA diagnostics offerings. We are committed to building a personalized and integrated health ecosystem in the fields of anti-aging, molecular pathology, immunity, neural health, and liquid biopsies for tumor markers and wound healing. We strive to deliver cutting-edge and proprietary technology in rapid diagnostics, leveraging artificial intelligence and data analytics to empower individuals with personalized and effective healthcare solutions, ultimately promoting health and wellness for all of humanity.

Industry
Biotechnology Research
Company size
2-10 employees
Headquarters
Singapore
Type
Privately Held
Founded
2023

Locations

Employees at GO-Dx Corporation Ltd

Updates

  • [Singapore, July 16, 2024] – GO-Dx Corporation Ltd (Aust) (Ticker: GD8), a forefront innovator in diagnostic and health profiling technologies, today proudly announces the commencement of trading of its shares on the National Stock Exchange (NSX). Founded with a mission to revolutionize diagnostic and precision medicine solutions, GO-Dx has swiftly emerged as a pivotal player in the healthcare technology sector. The NSX listing marks a significant milestone in the company’s trajectory, enhancing visibility and expanding accessibility to a broader investor community. Dr Lim Kah Meng, CEO of GO-Dx Corporation (Aust) Ltd, commented, “We are thrilled to embark on this new phase of growth and development as a publicly listed entity on the NSX. This milestone will empower us to fortify our market position, accelerate innovation, and drive sustained value creation for our shareholders.” The listing underscores GO-Dx’s unwavering commitment to transparency, accountability, and shareholder value. The company remains steadfast in advancing its mission to deliver state-of-the-art diagnostic and precision medicine solutions that elevate patient outcomes on a global scale. About GO-Dx Corporation Ltd (Aust) GO-Dx Corporation (Aust) Ltd is a pioneering healthcare technology company specializing in advanced diagnostic and precision medicine solutions. With a focus on innovation and customer-centricity, GO-Dx is dedicated to enhancing diagnostic and health profiling accuracy and efficiency across diverse healthcare settings. For detailed listing information, please visit https://lnkd.in/eB2XqXuA

    • No alternative text description for this image
  • GO-Dx participated in an event organized by the Australian Trade and Investment Commission at the Australian High Commission in Singapore on 20 August 2024. The event featured prominent participants from high-tech Life Sciences, Pharma and AI companies, including Stethy, Microsoft, Amazon Web Services (AWS), Advanced Health Intelligence, and Pfizer. Our CEO, Dr. Lim, presented on GO-Dx’s advancements in a broad range of proprietary diagnostic and health profiling capabilities, as well as new developments addressing unmet medical needs. Dr. Lim also served as a panelist, sharing his insights on how AI could drive innovations in healthcare in the near future.

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
      +9
  • [Singapore, 11 July 2024] – GO-Dx Corporation Ltd (Aust) (Ticker: GD8), a leading innovator in diagnostic and health profiling technologies, is pleased to announce that its shares will be listed and begin trading on the National Stock Exchange (NSX) under the ticker symbol GD8 on July 16, 2024. Founded with a commitment to revolutionizing diagnostic and precision medicine solutions, GO-Dx has rapidly emerged as a key player in the healthcare technology sector. The listing on NSX represents a significant milestone in the company's journey, providing enhanced visibility and access to a broader investor base. "We are excited to embark on this next chapter of growth and development as a publicly listed company on the NSX," said Dr Lim Kah Meng, CEO of GO-Dx Corporation (Aust) Ltd. "This listing will enable us to further strengthen our position in the market, accelerate innovation, and deliver long-term value to our shareholders." The NSX listing underscores GO-Dx's dedication to transparency, accountability, and shareholder value. The company remains committed to advancing its mission of delivering cutting-edge diagnostic and precision medicine solutions that improve and enhance patient outcomes globally. About GO-Dx Corporation (Aust) Ltd: GO-Dx Corporation (Aust) Ltd is a pioneering healthcare technology company specializing in advanced diagnostic and precision medicine solutions. With a focus on innovation and customer-centricity, GO-Dx is dedicated to enhancing diagnostic and health profiling accuracy and efficiency across diverse healthcare settings. For detailed listing information, please visit: https://lnkd.in/eB2XqXuA

    GO-Dx Corporation (Aust) Ltd Announces Listing on NSX

    GO-Dx Corporation (Aust) Ltd Announces Listing on NSX

    nsx.com.au

Similar pages